Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone415-374-7782
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$68.22 million
Profitability
Miscellaneous
Employees594
OptionableOptionable
InVitae (NYSE:NVTA) Frequently Asked Questions
What is InVitae's stock symbol?
InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."
How were InVitae's earnings last quarter?
InVitae Corp (NYSE:NVTA) issued its earnings results on Tuesday, August, 7th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07. The medical research company earned $37.31 million during the quarter, compared to the consensus estimate of $30.70 million. InVitae had a negative net margin of 109.60% and a negative return on equity of 103.37%. View InVitae's Earnings History.
When is InVitae's next earnings date?
How can I listen to InVitae's earnings call?
InVitae will be holding an earnings conference call on Tuesday, February 19th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8663934306.
What guidance has InVitae issued on next quarter's earnings?
InVitae issued an update on its FY 2019 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $220-220 million, compared to the consensus revenue estimate of $200 million.InVitae also updated its FY 2018 guidance to EPS.
What price target have analysts set for NVTA?
5 equities research analysts have issued 12 month target prices for InVitae's stock. Their predictions range from $16.00 to $20.00. On average, they anticipate InVitae's stock price to reach $17.6667 in the next year. This suggests a possible upside of 10.0% from the stock's current price. View Analyst Price Targets for InVitae.
What is the consensus analysts' recommendation for InVitae?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InVitae.
Has InVitae been receiving favorable news coverage?
Media coverage about NVTA stock has trended positive recently, according to InfoTrie. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. InVitae earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days.
Who are some of InVitae's key competitors?
Some companies that are related to InVitae include Guardant Health (GH), Genomic Health (GHDX), CareDx (CDNA), Natera (NTRA), Veracyte (VCYT), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), OpGen (OPGN) and CBA Florida (CBAI).
Who are InVitae's key executives?
InVitae's management team includes the folowing people:
- Dr. Randal W. Scott, Exec. Chairman (Age 61)
- Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 45)
- Ms. Shelly D. Guyer, Chief Financial Officer (Age 59)
- Mr. Lee Bendekgey, Chief Operating Officer (Age 61)
- Ms. Laura D'Angelo, Head of Investor Relations
When did InVitae IPO?
(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.
Who are InVitae's major shareholders?
InVitae's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.17%), Perceptive Advisors LLC (2.50%), Orbimed Advisors LLC (1.11%), Northern Trust Corp (1.06%), Geode Capital Management LLC (0.93%) and Millennium Management LLC (0.91%). Company insiders that own InVitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Eric Aguiar, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Institutional Ownership Trends for InVitae.
Which institutional investors are selling InVitae stock?
NVTA stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Bank of America Corp DE, MetLife Investment Advisors LLC, Barclays PLC, Bank of New York Mellon Corp, Bank of Montreal Can and Gabelli Funds LLC. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Katherine Stueland, Patty Dumond, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Insider Buying and Selling for InVitae.
Which institutional investors are buying InVitae stock?
NVTA stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, BlackRock Inc., Amundi Pioneer Asset Management Inc., Fiera Capital Corp, Daiwa SB Investments Ltd., Citigroup Inc. and D. E. Shaw & Co. Inc.. Company insiders that have bought InVitae stock in the last two years include Bros Advisors Lp Baker and Randal W Scott. View Insider Buying and Selling for InVitae.
How do I buy shares of InVitae?
Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is InVitae's stock price today?
One share of NVTA stock can currently be purchased for approximately $16.06.
How big of a company is InVitae?
InVitae has a market capitalization of $1.20 billion and generates $68.22 million in revenue each year. The medical research company earns $-123,380,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. InVitae employs 594 workers across the globe.
What is InVitae's official website?
How can I contact InVitae?
InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]
MarketBeat Community Rating for InVitae (NYSE NVTA)
MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote "Outperform" if you believe NVTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
